| Masi, Gianluca |
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma |
|
|
| Recruiting | 3 | 200 | Europe, US, RoW | Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | 05/26 | 08/26 | | |
| Recruiting | 2 | 46 | Europe | 166Holmium TARE, Cetuximab, Panitumumab, 5-Fluorouracil, Bevacizumab, Capecitabine | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer Metastatic | 11/26 | 02/27 | | |
TriComB, NCT04564898: Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. |
|
|
| Active, not recruiting | 1/2 | 48 | Europe | Capecitabine, Bevacizumab, Trifluridine/Tipiracil | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer Metastatic | 12/24 | 03/25 | | |
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy |
|
|
| Completed | 1/2 | 31 | Europe, US | NMS-01940153E | Nerviano Medical Sciences | Unresectable Hepatocellular Carcinoma (HCC) | 01/24 | 08/24 | | |
NCT05301465: Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab. |
|
|
| Recruiting | N/A | 50 | Europe | | University of Pisa | Gastric Cancer Stage IV | 11/22 | 06/23 | | |
| Falcone, Alfredo |
COLT, NCT03803436: Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation |
|
|
| Recruiting | 2 | 22 | Europe | Liver transplant, Chemotherapy | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Di Ricerche Farmacologiche Mario Negri, Gruppo Oncologico del Nord-Ovest | Liver Metastases, Colorectal Cancer Metastatic, Liver Neoplasm, Neoplasms | 01/24 | 01/24 | | |
